# Progenity

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/progenity

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.progenity.com
- Total disclosed funding: $39M
- Latest round: Series B (Aug 27, 2019)
- Investors on record: 1

## About

Based in California, US, and founded in 2010, Progenity, Inc. is a biotechnology company that develops and commercializes molecular testing products. Harry Stylli is the current CEO of the company. The company went public in 2020. In 2020, Progenity, Inc. raised USD 100.5 million in an IPO, selling 6.7 million shares at USD 15 per share on the NASDAQ, and became a publicly listed company under the ticker symbol PROG. In February 2021, the company raised USD 25 million in PIPE funding from unspecified investors.

The company develops genetic testing products including preparent (carrier test), innatal (prenatal screen), riscover (hereditary cancer testing), resura (prenatal test), and COVID-19 PCR Testing. The services that they offer are laboratory-developed prenatal genetic tests that can be used by patients, physicians, and clinicians to determine illnesses that can be passed to children.

Following the PIPE funding in February 2021, the company plans to use the net proceeds to support operations, invest in its molecular testing research and development program, invest in precision medicine platform research and development, and for working capital and general corporate purposes.

## Funding rounds

- Series B, Aug 27, 2019, $25M — Athyrium Capital Management
- Series A, Jun 27, 2013, $14M — Athyrium Capital Management

## Investors

- Athyrium Capital Management (https://capitalatlas.ai/funds/athyrium-capital-management) — Series A, Series B